Sai Life Sciences Limited (MAINBOARD)
Dec 11, 2024 - Dec 13, 2024
| Price | ₹522 - ₹549 |
| Premium | ₹72 |
|---|---|
| Lot size | 27 |
| Allotment | Dec 16, 2024 |
| Listing | Dec 18, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 27 | 14823 | 718422 |
| sHNI | 14 | 378 | 207522 | 7331 |
| bHNI | 68 | 1836 | 1007964 | 14662 |
Last updated on 13-Dec-2024 19:09:09
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 11084226 | 330125058 | 29.78 |
| HNIs | 8313169 | 41522058 | 4.99 |
| HNIs 10+ | 5542112 | 33813693 | 6.1 |
| HNIs 2+ | 2771056 | 7708365 | 2.78 |
| Retail | 19397393 | 26912412 | 1.39 |
| Total | 38794788 | 398559528 | 10.27 |
Application-Wise Breakup (Approx. no. of Apps) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 14662 | 9635 | 0.66 |
| HNIs (2-10L) | 7331 | 19613 | 2.68 |
| Retail | 718422 | 617915 | 0.86 |
| Total Applications: 647163 | |||
| © IPO Premium | |||
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIBs | 608.52 | 18123.87 | 29.78 |
| FIIs | - | 11326.35 | - |
| DIIs | - | 2728.21 | - |
| Mutual funds | - | 3669.73 | - |
| Others | - | 399.57 | - |
| HNIs | 456.39 | 2279.56 | 4.99 |
| HNIs 10+ | 304.26 | 1856.37 | 6.1 |
| HNIs 2+ | 152.13 | 423.19 | 2.78 |
| Retail | 1064.92 | 1477.49 | 1.39 |
| Total | 2129.83 | 21880.92 | 10.27 |
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹21.9 | @8% ₹25.1 | @9% ₹28.2 | @10% ₹31.4 | @11% ₹34.5 | @12% ₹37.6 |
Sai Life Sciences IPO Details
| Issue Size | [55421123] shares (aggregating up to ₹[3042.62] Cr) |
| Fresh Issue | [17304189] shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 38,116,934 shares of ₹1 (aggregating up to ₹[2092.62] Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 190,685,340 |
| Share holding post issue | 207,989,529 |
Sai Life Sciences IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Key Performance Indicator
| KPI | Sep-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 2.68% | 8.49% | 1.12% |
| ROCE | 3.90% | 10.26% | 5.13% |
| RONW | 2.68% | 8.50% | 1.13% |
| D/E | 0.73 | 0.75 | 0.8 |
| EPS (basic) | 1.49 | 4.53 | 0.55 |
| P/E Pre IPO | 126.42 | ||
| P/E Post IPO | 203.82 |
Company Financials
Sai Life Sciences Limited Financial Information (Restated Consolidated) In Crores.
| Period | Sep-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 2,476 | 2,275 | 2,186 | 2,164 |
| Revenue | 693 | 1,494 | 1,245 | 897 |
| Profit | 28 | 82 | 9 | 6 |
| Net Worth | 1,044 | 974 | 887 | 877 |
| Reserves | 855 | 953 | 867 | 859 |
| Borrowing | 764 | 710 | 699 | 751 |
About Company
Sai Life Sciences Limited, incorporated in January 1999, specializes in researching, developing, and manufacturing small-molecule new chemical entities, serving over 280 innovator pharmaceutical companies in FY 2024, including 230+ clients in September 2024 alone. The company collaborates with 18 of the top 25 pharmaceutical firms (by 2023 revenue), offering services across the US, UK, Europe, and Japan. Its offerings span CMC/CDMO capabilities, integrated discovery through CRO services, and support across biology, chemistry, and pharmacokinetics. Backed by a skilled workforce of 3,135 employees, including 2,353 scientific staff with 302 Ph.D.s and 1,475 master's degrees, Sai Life Sciences drives innovation with a business development team of 16 professionals strategically located globally.
Kotak Mahindra Capital Company Limited
Jefferies India Private Limited
Morgan Stanley India Company Pvt Ltd
Iifl Securities Ltd
Integrated Platform: Comprehensive services spanning drug discovery, development, and manufacturing.
Diverse Portfolio: Expertise in handling molecules across early-stage and commercial phases.
Advanced Capabilities: Cutting-edge technologies in biology, chemistry, and drug metabolism & pharmacokinetics (DMPK).
Dependency on Customers: Reliance on biotechnology and pharmaceutical clients exposes the company to risks from industry-specific challenges they face, including failures in drug development or manufacturing.
Compliance Risks: Inability to meet customer standards during audits and inspections could harm reputation and lead to project terminations.
Market Uncertainties: Shifts in customer demand or industry trends may adversely impact business performance and growth.
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/